{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:00:13Z","timestamp":1785218413788,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Radiotherapy r5emains a cornerstone of treatment for localized and locally advanced prostate cancer, yet substantial heterogeneity persists in oncological outcomes and treatment-related toxicity. Increasing evidence suggests that systemic inflammation, immune microenvironment characteristics, and tumor-specific molecular features contribute to these variations and may provide clinically relevant biomarkers. This narrative review summarizes current evidence regarding immunological and inflammatory biomarkers in prostate cancer treated with radiotherapy, focusing on their biological rationale, prognostic significance, predictive potential, and clinical applicability. Circulating biomarkers, including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein, fibrinogen, and cytokines such as IL-6 and TGF-\u03b21, have been associated with oncological outcomes and toxicity in several studies. However, their interpretation remains limited by biological nonspecificity, methodological heterogeneity, variable cutoff definitions, and lack of prospective validation. Within the tumor microenvironment, immune cell populations, including CD8\n                    <jats:sup>+<\/jats:sup>\n                    tumor-infiltrating lymphocytes, regulatory T cells, CD163\n                    <jats:sup>+<\/jats:sup>\n                    macrophages, and immune checkpoint molecules, provide insights into tumor\u2013immune interactions and radiotherapy-induced immune modulation. Emerging biomarkers such as extracellular vesicles, circulating tumor DNA, circulating tumor cells, and microRNAs offer promising opportunities for disease monitoring and treatment adaptation, although most evidence remains preliminary, particularly in localized disease. In contrast, genomic classifiers such as Decipher, Prolaris, and OncotypeDX currently represent the most clinically mature biomarker platforms for risk stratification and treatment decision support. Although several biomarkers demonstrate biological plausibility and prognostic value, few have sufficient clinical validation to guide routine radiotherapy decision-making. Future multicenter prospective studies, standardized biomarker assessment protocols, and integrated approaches combining clinical, imaging, molecular, and immune data are required to enable clinically actionable precision radiotherapy strategies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1801027","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:28Z","timestamp":1785216928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunological and inflammatory biomarkers of localized and locally advanced prostate cancer treated with radiotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Kanta","family":"Ka","sequence":"first","affiliation":[{"name":"Radiotherapy Department, Dalal Jamm Hospital","place":["Dakar, Senegal"]},{"name":"Service d\u2019Immunologie, Universit\u00e9 Cheikh Anta Diop de Dakar","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doudou Georges Massar","family":"Niang","sequence":"additional","affiliation":[{"name":"Service d\u2019Immunologie, Universit\u00e9 Cheikh Anta Diop de Dakar","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mame Daro","family":"Faye","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, McGill University Health Centre","place":["Montreal, QC, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Thiam","sequence":"additional","affiliation":[{"name":"Service de Canc\u00e9rologie, Dalal Jamm Hospital","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Institut Bergoni\u00e9","place":["Bordeaux, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Terlizzi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Jalloh","sequence":"additional","affiliation":[{"name":"Service d\u2019Urologie Hopital General Idrissa Pouye","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babacar","family":"Sine","sequence":"additional","affiliation":[{"name":"Service d\u2019Urologie Centre de Sant\u00e9 de Ngor","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Moustapha","family":"Dieng","sequence":"additional","affiliation":[{"name":"Aristide Le Dantec Hospital, Joliot Curie Institute of Cancer","place":["Dakar, Senegal"]},{"name":"Institut Africain de Lutte contre le Cancer","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidy","family":"Ka","sequence":"additional","affiliation":[{"name":"Service de Canc\u00e9rologie, Dalal Jamm Hospital","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babacar","family":"Mbengue","sequence":"additional","affiliation":[{"name":"Service d\u2019Immunologie, Universit\u00e9 Cheikh Anta Diop de Dakar","place":["Dakar, Senegal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: Introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.07.148","article-title":"French AFU Cancer Committee guidelines - update 2022-2024: Prostate cancer - diagnosis and management of localised disease","volume":"32","author":"Ploussard","year":"2022","journal-title":"Progres En Urol J Assoc Francaise Urol Soc Francaise Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrw007","article-title":"The impact of hypoxia and its modification of the outcome of radiotherapy","author":"Horsman","year":"2016","journal-title":"J Radiat Res (Tokyo)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216244","article-title":"Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer","volume":"566","author":"Zhang","year":"2023","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in prostate cancer: From a \u00ab cold \u00bb tumor to a \u00ab hot \u00bb prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-015-1494-7","article-title":"Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients","volume":"33","author":"Langsenlehner","year":"2015","journal-title":"World J Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijrobp.2015.07.1181","article-title":"Neutrophil count is associated with survival in localized prostate cancer","volume":"15","author":"Bahig","year":"2015","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000002544","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer: A systematic review and meta-analysis","volume":"95","author":"Yin","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29120745","article-title":"Comparative prospective and longitudinal analysis on the platelet-to-lymphocyte, neutrophil-to-lymphocyte, and albumin-to-globulin ratio in patients with non-metastatic and metastatic prostate cancer","volume":"29","author":"Salciccia","year":"2022","journal-title":"Curr Oncol Tor Ont"},{"key":"B12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12935-019-0785-2","article-title":"Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: A meta-analysis","volume":"19","author":"Peng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00345-024-05409-z","article-title":"Radiotherapy and inflammaging: The influence of prostate cancer radiotherapy on systemic inflammation","volume":"43","author":"Paal","year":"2024","journal-title":"World J Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-015-0841-3","article-title":"Early hematologic changes during prostate cancer radiotherapy predictive for late urinary and bowel toxicity","volume":"191","author":"Pinkawa","year":"2015","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"key":"B15","doi-asserted-by":"crossref","first-page":"19002","DOI":"10.1038\/s41598-020-75812-0","article-title":"Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients","volume":"10","author":"Stanojkovi\u0107","year":"2020","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1186\/s12885-022-10255-6","article-title":"Circulating levels of IL-6 and TGF-\u03b21 in patients with prostate cancer undergoing radiotherapy: Associations with acute radiotoxicity and fatigue symptoms","volume":"22","author":"Kop\u010dali\u0107","year":"2022","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1457839","DOI":"10.3389\/fimmu.2024.1457839","article-title":"Hypofractionated radiotherapy with simultaneous integrated boost for localized prostate cancer patients: Effects on immune system and prediction of toxicity","volume":"15","author":"D\u2019Auria","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s12672-025-02763-1","article-title":"Advance in prostate cancer biomarker discovery: Bridging detection, prognosis and therapeutics","volume":"16","author":"Das","year":"2025","journal-title":"Discov Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res","year":"2016","journal-title":"Cancer Discov"},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B21","article-title":"Prostate cancer immunotherapy: A review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010020","article-title":"Myeloid-derived suppressor cells in prostate cancer: Present knowledge and future perspectives","volume":"11","author":"Koinis","year":"2021","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8580043","article-title":"The roles of tumor-associated macrophages in prostate cancer","volume":"2022","author":"Han","year":"2022","journal-title":"J Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00874","article-title":"Immunomodulation of NK cells by ionizing radiation","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12885-020-07058-y","article-title":"Immune landscape of human prostate cancer: Immune evasion mechanisms and biomarkers for personalized immunotherapy","volume":"20","author":"Bou-Dargham","year":"2020","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24068","article-title":"High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy","volume":"81","author":"Yang","year":"2021","journal-title":"Prostate"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00498-6","article-title":"Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT","volume":"26","author":"Kane","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy141","article-title":"The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target","volume":"111","author":"Zhao","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-05-0658","article-title":"Multigene methylation analysis for detection and staging of prostate cancer","volume":"11","author":"Enokida","year":"2005","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0683","article-title":"IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda Cancer Institute","volume":"18","author":"Katongole","year":"2022","journal-title":"Future Oncol Lond Engl"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0019","article-title":"Immunotherapy of prostate cancer: Facts and hopes","volume":"23","author":"Bilusic","year":"2017","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"217568","DOI":"10.1097\/cco.0000000000000065","article-title":"Extracellular vesicle biomarkers redefine prostate cancer radiotherapy","volume":"616","author":"Chan","year":"2025","journal-title":"Cancer Lett"},{"key":"B38","doi-asserted-by":"crossref","first-page":"217184","DOI":"10.1016\/j.canlet.2024.217184","article-title":"Extracellular vesicle-derived biomarkers in prostate cancer care: Opportunities and challenges","volume":"601","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcdb.2015.02.010","article-title":"Extracellular vesicles in cancer: Exosomes, microvesicles and the emerging role of large oncosomes","volume":"40","author":"Minciacchi","year":"2015","journal-title":"Semin Cell Dev Biol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: Current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117746","article-title":"Liquid biopsy for precision diagnostics and therapeutics","volume":"554","author":"Anitha","year":"2024","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"B42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ajur.2023.01.002","article-title":"Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review","volume":"11","author":"Salciccia","year":"2024","journal-title":"Asian J Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040814","article-title":"External validation of an MRI-derived radiomics model to predict biochemical recurrence after surgery for high-risk prostate cancer","volume":"12","author":"Bourbonne","year":"2020","journal-title":"Cancers"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semradonc.2016.08.002","article-title":"Prostate cancer genetics: Variation by race, ethnicity, and geography","volume":"27","author":"Rebbeck","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1002\/pros.21265","article-title":"TMPRSS2\u2013ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and Japanese patients","volume":"71","author":"Magi-Galluzzi","year":"2011","journal-title":"Prostate"},{"key":"B46","doi-asserted-by":"publisher","first-page":"111039","DOI":"10.1007\/978-3-031-45489-9_14","article-title":"oDigital pathology biomarkers for guiding radiotherapy-based treatment concepts in prostate cancer - a systematic review and expert consensus","volume":"210","author":"Zamboglou","year":"2025","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"201.e9","DOI":"10.1016\/j.urolonc.2015.02.002","article-title":"Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy","volume":"33","author":"Langsenlehner","year":"2015","journal-title":"Urol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24100","article-title":"Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry","volume":"81","author":"Tan","year":"2021","journal-title":"Prostate"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1801027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:30Z","timestamp":1785216930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1801027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1801027"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1801027","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1801027"}}